The estimated Net Worth of Adam Hansard is at least $4.17 Million dollars as of 14 March 2024. Mr Hansard owns over 48,871 units of Applied Therapeutics stock worth over $3,818,508 and over the last 5 years he sold APLT stock worth over $348,755.
Sign up
Mr Hansard APLT stock SEC Form 4 insiders trading
Mr has made over 5 trades of the Applied Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 48,871 units of APLT stock worth $263,415 on 14 March 2024.
The largest trade he's ever made was selling 48,871 units of Applied Therapeutics stock on 14 March 2024 worth over $263,415. On average, Mr trades about 5,579 units every 85 days since 2020. As of 14 March 2024 he still owns at least 732,919 units of Applied Therapeutics stock.
You can see the complete history of Mr Hansard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Adam Hansard biography
Adam Hansard is the Chief Commercial Officer at Applied Therapeutics.
How old is Mr Hansard?
Mr Hansard is 45, he's been the Chief Commercial Officer of Applied Therapeutics since . There are 9 older and 2 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
What's Mr Hansard's mailing address?
Adam's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Insiders trading at Applied Therapeutics
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus, and Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
What does Applied Therapeutics do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does Applied Therapeutics's logo look like?
Complete history of Mr Hansard stock trades at Applied Therapeutics
Applied Therapeutics executives and stock owners
Applied Therapeutics executives and other stock owners filed with the SEC include:
-
shoshana Shendelman,
Chairman of the Board, President, Chief Executive Officer, Founder -
Riccardo Perfetti,
Chief Medical Officer -
Mark Vignola,
Chief Financial Officer -
Dr. Shoshana Shendelman Ph.D.,
Chair of the Board of Directors, Founder, Pres, CEO & Sec. -
Dr. Riccardo Perfetti,
Chief Medical Officer -
Leslie Funtleyder,
Independent Director -
Dr. Charles Silberstein M.D., CFA,
CFO & Head of Bus. Devel. -
Teena Lerner,
Lead Independent Director -
Joel Marcus,
Independent Director -
Stacy Kanter,
Independent Director -
Jay Skyler,
Independent Director -
Maeve Conneighton,
IR Contact Officer -
Adam Hansard,
Chief Commercial Officer -
Chids Mahadevan,
VP of Fin. & Chief Accounting Officer -
Real Estate Equities, Inc.A...,
-
Constantine Chinoporos,
See Remarks -
Charles Silberstein,
Chief Financial Officer -
Adam Hansard,
Chief Commercial Officer -
Corwin Dale Hooks,
Chief Commercial Officer -
Steven A. Ortega,
Principal Accounting Officer -
Chids Mahadevan,
See Remarks